Aducanumab and the certainty of evidence.

Jenny McCleery, Terence J Quinn

Registry-linked trialAbstract readEditorial

In one paragraph

Article in Age and ageing, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05877196 (Precision Medicine in Alzheimer's Disease), which is not on this map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05877196 narecruitingnot on this mapstarted 2023, after this paper: background citation

Precision Medicine in Alzheimer's Disease: A SMART Trial of Adaptive Exercises and Their Mechanisms of Action Using AT(N) Biomarkers to Optimize Aerobic-Fitness Responses (The FIT-AD SMART Trial)

TypeinterventionalSponsorArizona State UniversityRan2023 to 2028Enrolled216ConditionsMild Cognitive Impairment, Alzheimer Disease, Cognitive Impairment, Cognitive DeclineArmsModerate Intensity Continuous Training (MICT), Chair-based Stretch, High-Intensity Interval Training (HIIT), Combined Aerobic Resistance Exercise (CARE)

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Feasibility and preliminary effects of exercise interventions on plasma biomarkers of Alzheimer's disease in the FIT-AD trial: a randomized pilot study in older adults with Alzheimer's dementia.Pilot and feasibility studies · 2022
Article
Advance directives among cognitively impaired persons who had an amyloid PET scan and their care partners: a mixed-methods study.BMC palliative care · 2022
Article
Manipulation of the diet-microbiota-brain axis in Alzheimer's disease.Frontiers in neuroscience · 2022
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jenny McCleeryCochrane Dementia and Cognitive Improvement Group, University of Oxford, UK.

Terence J QuinnCochrane Dementia and Cognitive Improvement Group, University of Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Activities of Daily LivingAntibodies, Monoclonal, HumanizedHumansaducanumabAntibodies, Monoclonal, HumanizedaducanumabCochranedementiaevidenceolder people

Identifiers

PMID34405228

DOI10.1093/ageing/afab167

PMCPMC8581393

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

NCT05877196ClinicalTrials.gov

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.